Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Nuklearmedizin. 2022 Jun;61(3):231-239. doi: 10.1055/a-1759-2050. Epub 2022 Jun 3.
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.
I-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.
Many studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.
This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.
嗜铬细胞瘤和副神经节瘤（PPGL）是罕见的嗜铬细胞来源的神经内分泌肿瘤。目前有多种方法可用于治疗 PPGL 患者。这些治疗方法包括手术、化疗、分子靶向治疗和放射性药物。
碘-131 间碘苄胍（mIBG）是一种经典的放射性药物，可以通过特定的受体被摄取并定位于许多但不是所有的 PPGL 细胞中。
许多研究已经调查了 I-131 mIBG 治疗的疗效和毒性。这些研究报告了在客观、激素和症状反应以及患者可耐受的毒性方面的显著结果。
本文回顾了接受 I-131 mIBG 治疗 PPGL 的患者的报告经验，重点介绍了该治疗的功能和不足。
